Year: 2019

100% of evaluable patients in target dose had no relapse during the four-week follow-up periodIndependent objective EEG seizure analysis confirms target doseGanaxolone effective regardless of prior AED treatment and across diverse disease etiologies for RSEKOL call and live webcast on Monday, December 9th at 7:15am ETRADNOR, Pa., Dec. 07, 2019 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, announced additional data from its open-label, dose-finding Phase 2 study evaluating intravenous (IV) ganaxolone in patients with refractory status epilepticus (RSE).  The results were presented at the American Epilepsy Society (AES) annual meeting by Eugene...

AUSTIN, Texas, Dec. 06, 2019 (GLOBE NEWSWIRE) — Jones Energy II, Inc. (OTC: JEII) (“Jones Energy” or the “Company”) today announced that it has entered into a definitive merger agreement to be acquired by Revolution II WI Holding Company, LLC (“Revolution”), an affiliate of Mountain Capital Partners, LP (“Mountain Capital”), in an all-cash transaction valued at approximately $201.5 million. Under the terms of the merger agreement, which has been unanimously approved by the Jones Energy Board of Directors (the “Board”) and a majority of the Jones Energy stockholders, Jones Energy stockholders will receive approximately $14.11 in cash for each share of Jones Energy Class A common stock or each unit of Jones Energy Holdings II, LLC they own, as applicable. The transaction is expected to close in the first quarter of 2020.Jones Energy’s...

Not for Distribution to US Newswire Services or Dissemination in the United StatesLONDON, Ontario, Dec. 06, 2019 (GLOBE NEWSWIRE) — Indiva Limited (the “Company” or “Indiva”) (TSXV:NDVA) (OTCQX:NDVAF) is pleased to announce a strategic partnership with Dycar Pharmaceuticals Ltd. (“Dycar”) and a concurrent non-brokered unsecured convertible debenture financing of up to $4 million.DYCAR PRODUCTION AND DISTRIBUTION PARTNERSHIPIndiva has entered into a financing and white-label manufacturing arrangement with Dycar.  Under the terms of the letter agreement, Dycar will provide Indiva with initial non-dilutive financing of $3.1 million, and Indiva will manufacture and distribute certain Dycar-branded cannabis products from the Company’s licensed facility in London, Ontario.  The financing will be repaid by the deduction of Indiva services...

RICHMOND HILL, Ontario, Dec. 06, 2019 (GLOBE NEWSWIRE) — Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special meeting of shareholders held on December 6, 2019 (the “Meeting”). In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the Meeting.There were 20 shareholders represented in person or by proxy at the Meeting holding 83,464,785 common shares, representing approximately 66.80% of Helix’s total issued and outstanding shares.1.           Election of Directors

VANCOUVER, British Columbia, Dec. 06, 2019 (GLOBE NEWSWIRE) — Eco Oro Minerals Corp. (CSE:EOM) (the “Company” or “Eco Oro”) is pleased to announce that it has issued a US$6,500,000 demand promissory note (the “Promissory Note”) to Trexs Investments, LLC (“Trexs”). The Promissory Note will bear interest at a rate of 10% per annum and will be secured by a general security interest over all of the Company’s assets. The net proceeds from the Promissory Note will be used for general corporate purposes, including financing the Company’s ongoing arbitration with the Republic of Colombia. The Company may prepay the Promissory Note at any time without premium or penalty.In connection with the issuance of the Promissory Note, the US$7,000,000 “Second Tranche” of the Company’s previously announced US$35,000,000 private placement as set out...

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced the appointment of Robert M. Francomano as Chief Commercial Officer.Most recently, Mr. Francomano served as Senior Vice President, Global Head of Commercial and Medical Affairs for Stemline. Prior to this, Mr. Francomano garnered extensive oncology experience operating in global roles for Baxalta, Pfizer and GlaxoSmithKline, where he developed strategies for assets in clinical development from Phase I through Phase IV. His geographic responsibilities included the United States, the European Union, Latin America, and Asia-Pacific regions. Mr. Francomano also held positions of increasing responsibility within...

WINNIPEG, Manitoba, Dec. 06, 2019 (GLOBE NEWSWIRE) — DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (“Delta 9” or the “Company”), is pleased to announce that on December 4, 2019 it received an updated processing license from Health Canada. The license authorizes Delta 9 to sell cannabis extracts, cannabis topicals, and edible cannabis products as defined under the Cannabis Regulations (Canada). This development, following the Company’s submission to Health Canada of new product notifications for nine (9) new derivative cannabis products on November 5, 2019, means the Company will be authorized to begin sales of cannabis extracts on January 5, 2020“This is an exciting milestone for us,” said John Arbuthnot, CEO of Delta 9, “Our team has worked tirelessly toward our initial rollout of vaporizable oil cartridges, disposable vape oil...

ST. LOUIS, Dec. 06, 2019 (GLOBE NEWSWIRE) — Stifel Financial Corp. (“Stifel”) (NYSE: SF) today announced that it has completed the acquisition of substantially all of the capital markets business of GMP Capital Inc. (“GMP”) (TSX: GMP), a leading independent investment banking franchise based in Canada.  “We are building a premier investment bank focused on the middle market and this is yet another extension of executing on that strategy,” said Ronald J. Kruszewski, Chairman and CEO of Stifel. “The addition of GMP’s talented individuals expands our global business model into the vibrant Canadian market with a focus on technology, healthcare, cannabis, and energy verticals. We are excited to welcome Harris Fricker and his team to Stifel.” Founded in 1995, GMP’s capital markets business offers corporate clients and institutional investors...

Year 2018 consolidated net sales of VALMIERAS STIKLA ŠĶIEDRA, AS and its subsidiaries (hereinafter – VALMIERA GLASS GROUP or the GROUP) amounted to EUR 114.2 million. Compared to year 2017, the GROUP’s net sales have decreased by EUR 11.6 million (9.2% y-o-y). The consolidated operating profit (EBITDA) was negative and amounted to EUR -98.6 million, as opposed to EUR 18.4 million EBITDA and 14.7% EBITDA margin in 2017. Earnings before interest and taxes (EBIT) were negative in the amount of EUR -114.7 million (EUR 7.5 million in 2017). The GROUP’s net result for year 2018, attributable to the owners of the GROUP’s parent company, amounted to EUR -56.9 million.The negative result of year 2018 was caused by the poor financial performance of the GROUP’s subsidiary in the United States P-D VALMIERA GLASS USA Corp., and one-off accounting...

AS VALMIERAS STIKLA ŠĶIEDRA un tā meitasuzņēmumu (turpmāk tekstā – VALMIERA GLASS GRUPA vai GRUPA) konsolidētais neto apgrozījums 2018. gadā bija 114,2 miljoni EUR. Salīdzinājumā ar 2017. gadu GRUPAS neto apgrozījums ir samazinājies par 11,6 miljoniem EUR (9,2 %). Peļņa pirms procentu maksājumiem, nodokļiem, nolietojuma un amortizācijas (EBITDA) bija negatīva, proti, -98,6 miljoni EUR salīdzinājumā ar 18,4 miljoniem EUR vai 14,7 % EBITDA normas 2017. gadā. Peļņa pirms procentu maksājumiem un nodokļiem (EBIT) sastādīja -114,7 miljonus EUR (7,5 miljoni EUR 2017.gadā). GRUPAS neto zaudējumi, kas attiecināmi uz GRUPAS mātesuzņēmuma īpašniekiem 2018. gadā, bija 56,9 miljoni EUR.Šis negatīvais rezultāts ir saistīts ar sliktajiem GRUPAS meitasuzņēmuma P-D VALMIERA GLASS USA Corp. darbības rādītājiem ASV, kā arī vienreizējām grāmatvedības korekcijām,...